Cargando…

Performance evaluation of the PelvoCheck CT/NG test kit for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae

OBJECTIVE: Assessment of the performance of the PelvoCheck CT/NG test (Greiner-Bio-One GmbH) to detect Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) in first-void urine (FVU) of females. DESIGN: A cross-sectional study to compare the PelvoCheck CT/NG with COBAS TaqMan CT Test V.2.0 (Roch...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer, Thomas, Klos, Christian, Kofler, Regina, Kilic, Annett, Hänel, Kristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716231/
https://www.ncbi.nlm.nih.gov/pubmed/26729391
http://dx.doi.org/10.1136/bmjopen-2015-009894
_version_ 1782410527879725056
author Meyer, Thomas
Klos, Christian
Kofler, Regina
Kilic, Annett
Hänel, Kristina
author_facet Meyer, Thomas
Klos, Christian
Kofler, Regina
Kilic, Annett
Hänel, Kristina
author_sort Meyer, Thomas
collection PubMed
description OBJECTIVE: Assessment of the performance of the PelvoCheck CT/NG test (Greiner-Bio-One GmbH) to detect Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) in first-void urine (FVU) of females. DESIGN: A cross-sectional study to compare the PelvoCheck CT/NG with COBAS TaqMan CT Test V.2.0 (Roche) for the detection of CT and with an in-house porA-based PCR for the detection of NG in FVU specimens. In addition, pools of 5 FVU specimens containing only CT-negative or 1 CT-positive and 4 CT-negative samples were tested. Abbott RealTime CT/NG was used as an additional test to resolve discordant results. SETTING: Samples sent from six laboratories were tested at the University Medical Center Hamburg. PARTICIPANTS: Urine samples were from 1622 female patients attending gynaecological practices for chlamydia screening, another 120 urine samples were from patients pretested for NG at Synlab, Medical Service Center, Weiden GmbH. In addition, 50 urine samples spiked with various concentrations of reference material were used. RESULTS: For the detection of CT and NG, the sensitivity and specificity of the PelvoCheck CT/NG test were 98.8% and 100%, and 98.3% and 98.2%, respectively. The data obtained with the PelvoCheck CT/NG for pooled urine specimens resulted in a positive agreement of 90.9% and a negative agreement of 100%. CONCLUSIONS: The PelvoCheck CT/NG assay is a suitable test method for the detection of CT and NG in female FVU samples, with sensitivity and specificity comparable with other Food and Drug Administration approved CT/NG nucleic acid amplification tests. To the best of our knowledge, this is the first commercial test system validated for the analysis of pooled urine specimens. No false-positive or invalid result was observed in 55 analysed pools. Nevertheless, 5 samples were false negative due to a target concentration below the limit of detection of the PelvoCheck CT/NG test as a consequence of pooling-associated dilution.
format Online
Article
Text
id pubmed-4716231
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-47162312016-01-31 Performance evaluation of the PelvoCheck CT/NG test kit for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae Meyer, Thomas Klos, Christian Kofler, Regina Kilic, Annett Hänel, Kristina BMJ Open Diagnostics OBJECTIVE: Assessment of the performance of the PelvoCheck CT/NG test (Greiner-Bio-One GmbH) to detect Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) in first-void urine (FVU) of females. DESIGN: A cross-sectional study to compare the PelvoCheck CT/NG with COBAS TaqMan CT Test V.2.0 (Roche) for the detection of CT and with an in-house porA-based PCR for the detection of NG in FVU specimens. In addition, pools of 5 FVU specimens containing only CT-negative or 1 CT-positive and 4 CT-negative samples were tested. Abbott RealTime CT/NG was used as an additional test to resolve discordant results. SETTING: Samples sent from six laboratories were tested at the University Medical Center Hamburg. PARTICIPANTS: Urine samples were from 1622 female patients attending gynaecological practices for chlamydia screening, another 120 urine samples were from patients pretested for NG at Synlab, Medical Service Center, Weiden GmbH. In addition, 50 urine samples spiked with various concentrations of reference material were used. RESULTS: For the detection of CT and NG, the sensitivity and specificity of the PelvoCheck CT/NG test were 98.8% and 100%, and 98.3% and 98.2%, respectively. The data obtained with the PelvoCheck CT/NG for pooled urine specimens resulted in a positive agreement of 90.9% and a negative agreement of 100%. CONCLUSIONS: The PelvoCheck CT/NG assay is a suitable test method for the detection of CT and NG in female FVU samples, with sensitivity and specificity comparable with other Food and Drug Administration approved CT/NG nucleic acid amplification tests. To the best of our knowledge, this is the first commercial test system validated for the analysis of pooled urine specimens. No false-positive or invalid result was observed in 55 analysed pools. Nevertheless, 5 samples were false negative due to a target concentration below the limit of detection of the PelvoCheck CT/NG test as a consequence of pooling-associated dilution. BMJ Publishing Group 2016-01-04 /pmc/articles/PMC4716231/ /pubmed/26729391 http://dx.doi.org/10.1136/bmjopen-2015-009894 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Diagnostics
Meyer, Thomas
Klos, Christian
Kofler, Regina
Kilic, Annett
Hänel, Kristina
Performance evaluation of the PelvoCheck CT/NG test kit for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae
title Performance evaluation of the PelvoCheck CT/NG test kit for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae
title_full Performance evaluation of the PelvoCheck CT/NG test kit for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae
title_fullStr Performance evaluation of the PelvoCheck CT/NG test kit for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae
title_full_unstemmed Performance evaluation of the PelvoCheck CT/NG test kit for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae
title_short Performance evaluation of the PelvoCheck CT/NG test kit for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae
title_sort performance evaluation of the pelvocheck ct/ng test kit for the detection of chlamydia trachomatis and neisseria gonorrhoeae
topic Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4716231/
https://www.ncbi.nlm.nih.gov/pubmed/26729391
http://dx.doi.org/10.1136/bmjopen-2015-009894
work_keys_str_mv AT meyerthomas performanceevaluationofthepelvocheckctngtestkitforthedetectionofchlamydiatrachomatisandneisseriagonorrhoeae
AT kloschristian performanceevaluationofthepelvocheckctngtestkitforthedetectionofchlamydiatrachomatisandneisseriagonorrhoeae
AT koflerregina performanceevaluationofthepelvocheckctngtestkitforthedetectionofchlamydiatrachomatisandneisseriagonorrhoeae
AT kilicannett performanceevaluationofthepelvocheckctngtestkitforthedetectionofchlamydiatrachomatisandneisseriagonorrhoeae
AT hanelkristina performanceevaluationofthepelvocheckctngtestkitforthedetectionofchlamydiatrachomatisandneisseriagonorrhoeae